

POSTERS

P 01 HPV disease and COVID-19		
P 01-1	• Impact of the COVID-19 pandemic on HPV vaccinations in Switzerland and Greece: road to recovery	Gountas I. (Greece)
P 03 Epidemiology and natural history		
P 03-1	• Human development index and burden of cervical cancer: an ecological study	Hu J. (China)
P 03-2	• HPV genotypes distribution in urethral samples in French men	Bergeron C. (France)
P 03-3	• The burden of HPV-related cancer, precancerous lesions, and anogenital warts in Denmark during 2010-2021	Munk C. (Denmark)
P 03-4	• Prevalences of HPV and other sexually transmitted diseases among women living in remote areas along the Amazon rivers-Brazil	Liljander A. (Germany)
P 03-5	• Other HPV as important as HPV16 and 18 in developing High-Grade CIN?	Farzaneh F. (Canada)
P 03-6	• 10-year trend of vaccine-and non-vaccine-type high risk HPV among women in Western Austria	Borena W.. (Austria)
P 05 Immunology		
P 05-1	• Normalization of HPV-specific antibody detection in first-void urine: lessons learned from a pilot study	Bell M. (Belgium)
P 06 HPV prophylactic vaccines		
P 06-1	• Introduction of HPV vaccine in a country with low routine immunization coverage	Joksimović M. (Montenegro)
P 06-2	• Acceptance of human papillomavirus vaccination and parents' willingness to vaccinate their adolescents in Ethiopia: a systematic review and meta-analysis	Awoke Derby H. (Ethiopia)
P 06-3	• Effect of HPV vaccination on virus disappearance in a cervical swab in a cohort of HPV-positive Polish patients.	Pruski D. (Poland)
P 06-4	• Investigation of MTDOD multimerization platform on the immunogenicity of minor capsid protein L2-based prophylactic HPV vaccine antigens	Kaplan E. (Germany)

POSTERS

P 09 HPV testing		
P 09-1	• Coilocytosis in urine samples	Comes García M. D. (Spain)
P 09-2	• Comparison of anyplex™ HPV hr and Allplex™ HPV hr detection assays	Kloboves Prevodnik V. (Slovenia)
P 09-3	• The impact of HPV triage on CIN2+ cumulative incidence in Slovenian national cervical cancer screening program Zora	Kos J. (Slovenia)
P 09-4	• High risk HPV-specific testing in oropharyngeal carcinoma by RNA ISH has clinical value beyond p16 IHC	Wrobel S. (USA)
P 09-5	• Assessment of HPV characteristics in cervical cancer screening samples from elderly women - a new stratification tool?	Andersen K. (Denmark)
P 09-6	• Clinical validation of Allplex HPV hr detection assay on surepath collected cervical samples: comparison with Clart® HPV4s genotyping test in a French laboratory	Daste G. (France)
P 09-7	• Completing the international validation status of the Ampfire® HPV screening 16/18/hr assay	Chung J. (Belgium)
P 09-8	• The detection of multiple human papillomavirus (HPV) types through the development of an isothermal DNA amplification assay	Powell L. (Ireland)
P 10 HPV screening		
P 10-1	• Does the oncogenic potential and genotypic prevalence of HPV change every year?	Zivadinovic R. (Serbia)
P 10-3	• An economic evaluation of two cervical screening algorithms in Belgium: HPV primary compared to HPV and liquid-based cytology (LBC) co-testing	Bogers J. P. (Belgium)
P 10-4	• HrHPV infection prevalence in women with NILM cytology	Dinis S. (Portugal)
P 10-5	• Comparison of clinical efficacy of human papillomavirus (HPV) testing with partial genotyping to liquid-based cytology as primary test in cervical screening for women between 25 and 29 years old in Singapore	Ang J. X. (Singapore)
P 10-6	• Cervical cancer incidence and screening in Sweden 2017-2022	Andersson H. (Sweden)
P 10-7	• HPV prevalence and genotype profile in primary HPV screening of norwegian women aged 25-33 years	Fonn J. S. (Norway)
P 10-8	• High risk HPV genotypes prevalence in Mexico	García Gil A. (Mexico)
P 10-9	• Evaluation of a new self-sampling device for HPV detection in cervical cancer screening	Haba Moya J. (Spain)
P 10-10	• Efficacy and acceptability of self-collected medical grade tampon as a novel vaginal sample collection tool for the detection of HPV and STIS	Milanova V. (Bulgaria)
P 10-11	• Prevalence of the human papillomavirus (HPV) types among cervical dysplasia women attending a gynaecological clinic in Sweden	Romero García F. (Sweden)



POSTERS

P 11		Screening for women difficult to reach
P 11-1	<ul style="list-style-type: none"> Enhancing cervical cancer screening for Dutch women over 60: evaluating the need for regular screening at age 65 	Jemal E. (Netherlands)
P 11-2	<ul style="list-style-type: none"> Identifying barriers and facilitators to implementing a community health worker (CHW)-engaged cervical cancer screening program in Shenzhen, China using the Consolidated Framework for Implementation Research (CFIR) 	Wanyi T. (USA)
P 11-3	<ul style="list-style-type: none"> Barriers to follow-up care after a positive HPV test among Hispanic women in the United States 	Canedo J. (USA)
P 12		Triage of HPV positive women
P 12-1	<ul style="list-style-type: none"> High-risk human papillomavirus testing is superior to visual inspection with acetic acid in cervical cancer screening of Kenyan and Ugandan women living with HIV 	Ermel A. (USA)
P 13		Self-sampling
P 13-1	<ul style="list-style-type: none"> Clinical performance of hr-HPV testing on self-taken vaginal samples for the detection of CIN2+ and CIN3+ over three screening rounds 	Stanczuk G. (UK)
P 13-2	<ul style="list-style-type: none"> HPV self-sampling pilot and program implementation strategies used to engage under screened communities in cervical cancer screening: a scoping review 	Fullerton M. (Canada)
P 13-3	<ul style="list-style-type: none"> Cost-effectiveness of HPV self-sampling recruitment strategies for cervical cancer screening compared to clinician-sampling in Singapore 	Chua B. (Singapore)
P 13-4	<ul style="list-style-type: none"> A nationwide trial of risk-stratified cervical screening for faster cervical cancer elimination 	Hassan S. S. (Sweden)

POSTERS

P 14		Genotyping
P 14-1	<ul style="list-style-type: none"> Prevalence and genotype distribution of human papillomavirus (HPV) in penile cancer in Brazil: systematic literature review and meta-analysis 	Saddi V. A. (Brazil)
P 14-2	<ul style="list-style-type: none"> Prevalence of HPV and assessing type-specific hpv testing in cervical high-grade squamous intraepithelial lesions in Poland 	Przybylski M. (Poland)
P 14-3	<ul style="list-style-type: none"> Analytical comparison of Allplex HPV hr and Anyplex HPV hr in population-based cervical cancer screening setting 	Bohinc K. (Slovenia)
P 14-4	<ul style="list-style-type: none"> Evaluating the performance of two screenfire HPV genotyping assays on various PCR platforms 	Hou L. (USA)
P 14-5	<ul style="list-style-type: none"> Risk stratification for cervical neoplasia by HPV genotypes and cytology results in pilot HPV-based screening "Hippo" project 	Nowakowski A. (Poland)
P 15		Molecular markers
P 15-1	<ul style="list-style-type: none"> CTLA4 polymorphisms (rs5742909, rs231775, rs3087243) influence on HPV vulnerability, intraepithelial lesions, and cervical cancer susceptibility 	De Oliveira K. B. (Brazil)
P 15-2	<ul style="list-style-type: none"> Genetic (CHRNA5, SCL6A4) and epigenetic (BDNF, NTRK2) contributions to cervical carcinoma or precursor lesions 	Bicho C. (Portugal)
P 15-3	<ul style="list-style-type: none"> Identifying molecular biomarkers of cervical disease progression 	Scott H. (UK)
P 15-4	<ul style="list-style-type: none"> Programmed Death-Ligand 1 expression in uterine cervical carcinoma in Indian population 	Sinha R. (India)
P 15-5	<ul style="list-style-type: none"> Plasma cell-free DNA concentration and fragmentomes predict neoadjuvant chemotherapy response in cervical cancer patients 	Ting P. (China)
P 16		Screening methods
P 16-1	<ul style="list-style-type: none"> The 2023 global HPV screening proficiency study 	Carlsson S. (Sweden)



POSTERS

P 17		Methylation
P 17-1	• WID-qCIN - optimization and recalibration of a DNA-methylation based test to triage HPV-positive women	Schreiberhuber L. (Austria)
P 17-2	• Screening and functional study of methylation modification of genes associated with cervical cancer	Ling X. (China)
P 17-3	• Feasibility of FAM19A4/mir124-2 DNA methylation test for cervical and endometrial glandular lesions in formalin-fixed paraffin-embedded histology - a pilot study	Bouda J. (Czech Republic)
P 17-4	• Clinical validation of methylation triage assays: the VALMETH concept	Redzic N. (Belgium)
P 18		Microbiome
P 18-1	• The role of the vaginal microbiome and the immune system in the process of cervical carcinogenesis	Kudela E. (Slovakia)
P 18-2	• Cervicovaginal bacterial infections and HPV-DNA positivity in females of reproductive age harbouring cervical dysplasias	Valasoulis G. (Greece)
P 19		Serology
P 19-1	• Serosurveillance to support the HPV vaccination programme in England: durability of antibody responses against vaccine and non-vaccine types 3-4, 8-9 and 13-14 years after each programmatic change	Panwar K. (UK)
P 20		New technologies
P 20-1	• Potential of AI technology and digital cytology in cervical cancer screening: an evaluation of the hologic geniustm digital cytology system	Smith D. (UK)
P 20-2	• Metabolomic profiling of cervical mucus for diagnosis and pathway analysis in cervical neoplasia	Fuji T. (Japan)

POSTERS

P 21		Artificial intelligence – Big data – Machine learning
P 21-1	• Artificial intelligence in cervical colposcopy: a review	Nauschütte L. (Germany)
P 21-2	• A.I. strategies for predicting regression potential in H&E images of cervical precancerous lesions	Lehtonen O. (Finland)
P 21-3	• Development and validation of artificial intelligence-based analysis software to support screening system of cervical intraepithelial neoplasia	Ouh Y. T. (South Korea)
P 22		Diagnostic procedures / management
P 22-1	• Clinical factors influencing the occurrence of discordant results between cytology, colposcopy and histopathology in the diagnosis of cervical lesions	Dordea Leonte L. (Romania)
P 24		Colposcopy
P 24-1	• Can pre-treatment with vaginal estrogen improve the colposcopy performance in postmenopausal women? - a randomized controlled trial	Bertelsen V. M. (Denmark)
P 24-2	• Complete visualization of transformation zone in colposcopy using estradiol or misoprostol: a clinical trial	Yarandi F. (USA)



POSTERS

P 25 Cervical neoplasia		
P 25-1	• P16/ki67 dual stain cytology in cervical smears: is it still useful?	Mitran M. (Romania)
P 25-2	• Postoperative prognosis of patients harboring human papillomavirus who underwent minimally invasive radical trachelectomy for early-stage cervical cancer	Shin-Wha L. (South Korea)
P 25-3	• Clinical, economic, and humanistic burden of high grade cervical intraepithelial neoplasia in Europe: systematic literature review	Valente S. (Germany)
P 25-4	• Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer	Holzhauser S. (Sweden)
P 25-5	• One carbon metabolism and CIN	Baturan B. (Serbia)
P 25-6	• Genomic risk variants and HPV infection modulate gene expression at the human leukocyte antigen locus in cervical cancer	Ramachandran D. (Germany)
P 26 Vulvar diseases and neoplasia		
P 26-1	• Association of human papilloma virus infection with other microbial pathogens in cervical samples with normal and abnormal cytopathological findings	Aleksioska Papestiev I. (Macedonia)

POSTERS

P 29 HPV and oropharynx / Head and neck cancer	
P 29-1	<ul style="list-style-type: none"> Evaluating diagnostic workflows for HPV-positive oropharyngeal squamous cell carcinoma detection using simulated specimens mounted on slides <p style="text-align: right;">Zhelev P. (Canada)</p>
P 29-3	<ul style="list-style-type: none"> Evaluation of a prognostic HPV biomarker assay for risk stratification of HPV16+ oropharyngeal squamous cell carcinoma patients <p style="text-align: right;">Kloch Bendtsen S. (Denmark)</p>
P 29-4	<ul style="list-style-type: none"> Incidence and prevalence of human papillomavirus in tonsillar and base of tongue cancer during 2000-2022 in the Stockholm region and Sweden <p style="text-align: right;">Jörtsö E. (Sweden)</p>
P 29-5	<ul style="list-style-type: none"> HPV related oropharyngeal cancers in Canada: HPV oral scan <p style="text-align: right;">Racovitan V. (Canada)</p>
P 29-6	<ul style="list-style-type: none"> Circulating and salivary DNA-based biomarkers for early diagnosis and recurrence monitoring of OPSCC <p style="text-align: right;">Bouska O. (Czech Republic)</p>
P 29-7	<p>Studies on the effects of curcumin targeting CDC27 alone or combined with other inhibitors on HPV positive and negative head and neck cancer cell lines</p> <p style="text-align: right;">Zupancic M. (Sweden)</p>
P 29-8	<ul style="list-style-type: none"> Combining specific PI3K, PARP, and WEE1 inhibitors or corresponding single inhibitors with radiotherapy in HPV positive and negative tonsillar squamous cell carcinoma cell lines reveals synergistic effects, while the effects with APR-246 are limited <p style="text-align: right;">Kostopoulou O. N. (Sweden)</p>
P 30 HPV and associated skin diseases	
P 30-1	<ul style="list-style-type: none"> Oncological treatment to men with penile cancer, survival in correlation to treatment and HPV-status <p style="text-align: right;">Ulvskog E. (Sweden)</p>
P 32 HPV transmission	
P 32-1	<ul style="list-style-type: none"> Regression of HPV-derived VaIN using an adjuvant treatment with a coriolus versicolor-based vaginal gel <p style="text-align: right;">Lopez Cavanillas B. (Spain)</p>



POSTERS

P 34 Conventional therapies		
P 34-1	• Remission of HPV-related diseases during antiviral treatment of herpes virus: a case series	Falucci S. (Italy)
P 35 Economics and modelling		
P 35-1	• Health economic impact model of a digital health solution	Ruiz Serrano A. (Switzerland)
P 35-2	• Financial difficulty in acquiring menstrual hygiene products in Lithuania	Simanaukaite A. (Lithuania)
P 35-3	• Health impact and cost-effectiveness analysis of nonavalent versus bivalent human papillomavirus national immunization strategies in Thailand	Wu Y. H. (Taiwan)
P 35-4	• Community-driven software development for HPV modeling: reflections and lessons learned	Stuart R. (USA)
P 37 Health education		
P 37-1	• Factors affecting young women's participation in cervical cancer testing - a population-based survey study	Partanen V. M. (Finland)
P 37-2	• It's time: a campaign to increase HPV vaccination awareness and cervical cancer screening among Hispanic/Latina and Korean women	Baezconde-Garbanati L. (USA)
P 37-3	• HPV decide: the development of a comprehensive tool for facilitating informed HPV vaccination choices among adults aged 27 to 45	Wheldon C. (USA)
P 37-4	• A descriptive study of first female South African HPV vaccine recipients eleven years later: sociodemographics, sexual behaviour and knowledge	Adams R. (South Africa)
P 37-5	• Identifying educational needs for anal cancer prevention among patients taking pre-exposure prophylaxis (PREP)	Maness S. (USA)
P 37-6	• A pilot evaluation of a sexual health high-school educational intervention on HPV knowledge, beliefs and behaviours	Norris T. (Canada)

POSTERS

P 38		Low resource settings
P 38-1	• Nonvaccine oncogenic human papillomavirus (HPV) - 35: the most prevalent HPV genotype among Gabonese women	Mabika Obanda A. K. F. (Gabon)
P 39		Public health
P 39-1	• Surveillance of adverse events following national HPV vaccine immunization in Taiwan	Chen Y. C. (Taiwan)
P 39-2	• Epidemiological characteristic of p16 among oropharyngeal squamous cell carcinoma in a oral cancer endemic area	Liu P. T. (Taiwan)
P 39-3	• Cervical cancer prevention in rural Kenyan communities: the mother-daughter project	Tong Y. (USA)
P 39-4	• Informatics platform for a cervical cancer elimination campaign using HPV vaccination and HPV screening	Ure A. E. (Sweden)
P 39-5	• Children's perceptions about being offered the HPV vaccination: a focus group study	Enskär I. (Sweden)
P 39-6	• Using immunization registry data to explore disparities in early HPV vaccine initiation in a rural, midwestern state, US	Ryan G. (USA)
P 39-7	• The opinion of women aged 16-55 on free or partially subsidized menstrual hygiene products in Lithuania and its influential factors	Krutulyte D. (Lithuania)
P 39-8	• Impact of the pandemic on cervical cancer screening in the state of Rio de Janeiro - Brazil	Silveira F. A. (Brazil)
P 39-9	• Knowledge regarding menstrual cycle and menstrual hygiene of Lithuanian women aged 16-55 years	Jariene K. (Lithuania)
P 40		Fertility and HPV
P 40-1	• HPV and recurrent pregnancy loss	Drakakis P. (Greece)
P 40-2	• Cervical adenocarcinoma in nulliparous woman - is it possible for a patient to become a mother?	Musialowicz V. (Poland)
P 40-3	• Associations between loop electrosurgical excision (LEEP) for cervical precancer after primary human papillomavirus (HPV) screening and adverse birth outcomes	Ogilvie G. (Sweden)

